Welcome to our dedicated page for KMPH news (Ticker: KMPH), a resource for investors and traders seeking the latest updates and insights on KMPH stock.
Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect KMPH's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.
Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of KMPH's position in the market.
KemPharm (NASDAQ: KMPH), a specialty pharmaceutical company, announced participation in BIO @ JPM and Fierce JPM Week 2021, held virtually in January. The management team will engage in one-on-one meetings to discuss recent achievements and potential milestones, highlighting KP415, an investigational product for ADHD, with a PDUFA date set for March 2, 2021. KP415 aims to enhance ADHD treatment by improving action onset and duration while minimizing adverse effects associated with traditional medications.
KemPharm, Inc. (NASDAQ: KMPH) has announced the pricing of an underwritten public offering of 7,692,307 shares of common stock at $6.50 each, amounting to gross proceeds of approximately $50 million. The offering, which includes warrants for the same number of shares, is set to close on or about January 12, 2021. Roth Capital Partners is the sole manager of this offering, which follows the recent registration statement declared effective by the SEC on January 7, 2021. KemPharm’s stock will begin trading on The Nasdaq Capital Market under the ticker symbol “KMPH” from January 8, 2021.
KemPharm, Inc. (OTCQB: KMPH) has expanded its agreement with Corium, Inc. to provide product development consultation services, potentially bringing in up to $15.6 million in service fees through March 31, 2022. This agreement follows the 2019 License Agreement with Gurnet Point Capital for the exclusive rights to develop KemPharm’s SDX product candidates, including KP415. The new arrangement enhances revenue visibility and extends the revenue stream related to KP415 beyond its PDUFA date of March 2, 2021, indicating strong collaboration and confidence in the product's potential commercialization.
KemPharm (OTCQB: KMPH) announced significant progress in its Letter to Shareholders ahead of the 2020 Annual Meeting. The FDA accepted the New Drug Application (NDA) for KP415, an ADHD treatment, with a PDUFA date set for March 2, 2021. As a result, KemPharm received a $5 million milestone payment from Gurnet Point Capital. The ADHD market, valued at $17.9 billion in 2019, presents a substantial opportunity, with KP415 aiming to address unmet needs. Recent patent issuances ensure IP protection for SDX until at least 2037. Despite challenges, KemPharm's outlook remains optimistic for future growth.
KemPharm, Inc. (Nasdaq: KMPH) reported financial results for Q1 2020, highlighting a revenue increase to $2.1 million from $1.4 million in Q4 2019. The FDA accepted the NDA for KP415, triggering a $5 million milestone payment from GPC. The anticipated PDUFA date for KP415 is in March 2021. Despite a net loss of $5.8 million, down from $12.3 million in Q1 2019, the company has extended its cash runway. However, KemPharm is at risk of delisting from Nasdaq if it fails to meet specific market value and bid price requirements by May 13, 2020.
KemPharm, Inc. (Nasdaq: KMPH), a specialty pharmaceutical company, will host a conference call on May 12, 2020, at 5:00 p.m. ET, to discuss its Q1 2020 corporate and financial results. Interested participants can join by dialing (866) 395-2480 (U.S.) or (678) 509-7538 (international) using Conference ID 5753768. An accompanying audio webcast and slide presentation will be available on the investor relations section of KemPharm's website, with an archive accessible for 90 days post-event. KemPharm focuses on developing proprietary prodrugs for serious medical conditions, including ADHD.
FAQ
What is the market cap of KMPH (KMPH)?
